[go: up one dir, main page]

AR088165A1 - Proteinas de funcion dual para tratar trastornos metabolicos - Google Patents

Proteinas de funcion dual para tratar trastornos metabolicos

Info

Publication number
AR088165A1
AR088165A1 ARP120103552A ARP120103552A AR088165A1 AR 088165 A1 AR088165 A1 AR 088165A1 AR P120103552 A ARP120103552 A AR P120103552A AR P120103552 A ARP120103552 A AR P120103552A AR 088165 A1 AR088165 A1 AR 088165A1
Authority
AR
Argentina
Prior art keywords
metabolic disorders
dual function
treat metabolic
disorders associated
function proteins
Prior art date
Application number
ARP120103552A
Other languages
English (en)
Inventor
R Boettcher Brian
L Caplan Shari
E Cellitti Susan
S Daniels Douglas
Hubert Geierstanger Bernhard
Licht Stuart
Hamamatsu Norio
Loew Andreas
Craig Weldon Stephen
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47023090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of AR088165A1 publication Critical patent/AR088165A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud se refiere a la identificación de proteínas que comprenden el factor de crecimiento de fibroblastos 21 (FGF21) y otros reguladores metabólicos, incluyendo variantes de los mismos, conocidos por modificar los perfiles metabólicos en sujetos en quienes se administren. También se divulgan métodos para tratar trastornos asociados con el FGF21, trastornos asociados con GLP-1 y trastornos asociados con Exendina-4, incluyendo condiciones metabólicas.
ARP120103552A 2011-09-26 2012-09-26 Proteinas de funcion dual para tratar trastornos metabolicos AR088165A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539290P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
AR088165A1 true AR088165A1 (es) 2014-05-14

Family

ID=47023090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103552A AR088165A1 (es) 2011-09-26 2012-09-26 Proteinas de funcion dual para tratar trastornos metabolicos

Country Status (27)

Country Link
US (2) US9458214B2 (es)
EP (1) EP2764019B1 (es)
JP (1) JP6152380B2 (es)
KR (1) KR102217254B1 (es)
CN (2) CN106432510A (es)
AP (1) AP2014007544A0 (es)
AR (1) AR088165A1 (es)
AU (1) AU2012316132A1 (es)
BR (1) BR112014007086A2 (es)
CA (1) CA2849760A1 (es)
CL (1) CL2014000737A1 (es)
CO (1) CO6920258A2 (es)
CR (1) CR20140141A (es)
CU (1) CU20140035A7 (es)
EA (1) EA201490697A1 (es)
GT (1) GT201400056A (es)
IL (1) IL231647A0 (es)
MA (1) MA35507B1 (es)
MX (1) MX350840B (es)
PE (1) PE20141542A1 (es)
PH (1) PH12014500659A1 (es)
SG (1) SG11201400596QA (es)
TN (1) TN2014000110A1 (es)
TW (1) TW201315742A (es)
UY (1) UY34347A (es)
WO (1) WO2013049234A2 (es)
ZA (1) ZA201401699B (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP4306165A3 (en) 2011-07-01 2024-04-17 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015513912A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． タンパク質の産生のための修飾ポリヌクレオチド
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
AR092076A1 (es) * 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
WO2014037373A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9925242B2 (en) 2012-12-27 2018-03-27 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
JP2016505613A (ja) * 2013-01-03 2016-02-25 オラムド エルティーディー． Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
CA2945240C (en) * 2014-04-11 2021-08-03 Universite Catholique De Louvain Transgenic pig islets and uses thereof for treating diabetes
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA2994279A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами
EP3463427A4 (en) 2016-05-25 2020-03-11 Board of Regents, The University of Texas System METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
CA3042512A1 (en) 2016-11-10 2018-05-17 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
BR112019010250A2 (pt) 2016-11-22 2019-09-17 Klotho Therapeutics Inc novas proteínas klotho recombinantes e composições e métodos que envolvem as mesmas
CA3047862A1 (en) * 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2018194413A1 (en) * 2017-04-21 2018-10-25 Yuhan Corporation Method for producing dual function proteins and its derivatives
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
BR112020008936A2 (pt) * 2017-11-06 2020-10-20 Shire-Nps Pharmaceuticals, Inc. análogos e pepticorpos de glp-2 para administração antes, durante ou após a cirurgia
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (zh) * 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN119386161A (zh) 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN113603794B (zh) * 2018-01-11 2024-01-16 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
JP7475276B2 (ja) * 2018-02-08 2024-04-26 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｆｇｆ２１バリアント、融合タンパク質及びそれらの適用
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
WO2019243557A1 (en) * 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
MX2021000016A (es) 2018-07-03 2021-03-09 Bristol Myers Squibb Co Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
CA3114803A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
MA55008A (fr) * 2019-02-20 2021-12-29 Novo Nordisk As Aminoacyl-arnt synthétases et leurs utilisations
AU2020230668B2 (en) * 2019-03-05 2025-05-29 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) * 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP7767325B2 (ja) * 2020-06-03 2025-11-11 ケブンハウンス、ウニバーシテート Ｇｌｐ１ｒアゴニスト・ｎｍｄａｒアンタゴニストコンジュゲート
CA3184546A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
CN113105561B (zh) * 2021-04-30 2021-12-03 江南大学 一种双靶点融合蛋白的制备方法和应用
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
WO2023099723A1 (en) * 2021-12-02 2023-06-08 Københavns Universitet Peptide-drug conjugates for treatment of neurodegenerative diseases
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
JP2025537240A (ja) * 2022-11-07 2025-11-14 ビーピー アセット ナイン、インコーポレイテッド Ｎａｓｈ治療のためのｆｇｆ２１タンパク質変異体
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JP2583257B2 (ja) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
JP2003535037A (ja) 1999-12-23 2003-11-25 ザイモジェネティクス，インコーポレイティド 炎症を治療する方法
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
MXPA05007210A (es) * 2003-11-13 2006-02-10 Hanmi Pharm Ind Co Ltd Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo.
AU2004303783A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
JP2008528487A (ja) * 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
EP3260129A1 (en) 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
AU2009302318A1 (en) 2008-10-10 2010-04-15 Amgen Inc. FGF21 mutants and uses thereof
AU2009308163B2 (en) 2008-10-24 2013-01-10 Novartis Ag Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
CN101812474A (zh) * 2009-02-25 2010-08-25 李慎涛 骨保护素-热休克蛋白65融合蛋白的制备及其应用
WO2010129600A2 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TWI436776B (zh) * 2009-05-05 2014-05-11 Amgen Inc Ｆｇｆ２１突變體及其用途
JP2012529463A (ja) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Also Published As

Publication number Publication date
JP2014527986A (ja) 2014-10-23
BR112014007086A2 (pt) 2017-03-28
EP2764019A2 (en) 2014-08-13
MX350840B (es) 2017-09-19
KR102217254B1 (ko) 2021-02-19
IL231647A0 (en) 2014-05-28
PH12014500659A1 (en) 2014-05-19
US9458214B2 (en) 2016-10-04
CN104024273B (zh) 2016-10-12
US20170166621A1 (en) 2017-06-15
KR20140069249A (ko) 2014-06-09
US20130129724A1 (en) 2013-05-23
SG11201400596QA (en) 2014-09-26
CN106432510A (zh) 2017-02-22
WO2013049234A3 (en) 2014-01-03
AP2014007544A0 (en) 2014-03-31
MX2014003676A (es) 2015-03-20
UY34347A (es) 2013-04-30
GT201400056A (es) 2015-09-23
WO2013049234A2 (en) 2013-04-04
US10669323B2 (en) 2020-06-02
TN2014000110A1 (en) 2015-07-01
CR20140141A (es) 2014-07-15
PE20141542A1 (es) 2014-10-31
CL2014000737A1 (es) 2014-10-03
EP2764019B1 (en) 2019-04-03
EA201490697A1 (ru) 2014-11-28
JP6152380B2 (ja) 2017-06-21
CU20140035A7 (es) 2014-08-28
AU2012316132A1 (en) 2014-04-17
MA35507B1 (fr) 2014-10-02
TW201315742A (zh) 2013-04-16
ZA201401699B (en) 2015-04-29
CA2849760A1 (en) 2013-04-04
CN104024273A (zh) 2014-09-03
CO6920258A2 (es) 2014-04-10

Similar Documents

Publication Publication Date Title
AR088165A1 (es) Proteinas de funcion dual para tratar trastornos metabolicos
CU20140034A7 (es) Proteínas de fusión para tratar trastornos metabólicos
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112014003704A2 (pt) moduladores ror gama
MX2015013939A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112013029062A2 (pt) lixisenatida e metformina para o tratamento de diabetes tipo 2
ECSP12012288A (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
BR112014000889A2 (pt) tratamento para hipoxia
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
BR112014032802A2 (pt) composições compreendendo fenóis substituídos e aplicação tópica das mesmas
WO2012173781A3 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
FB Suspension of granting procedure